Funding for this research was provided by:
Goethe-Universität Frankfurt am Main (n.a.)
Novartis Pharma (n.a.)
Bristol-Myers Squibb Foundation (n.a.)
José Carreras Leukämie-Stiftung (n.a.)
Received: 8 January 2020
Accepted: 6 September 2020
First Online: 29 September 2020
Ethics approval and consent to participate
: Written informed consent was obtained from all individual participants before inclusion into the study. The study has been approved by the responsible local ethics committee: Ethikkommission des Fachbereichs Medizin, Universitätsklinikum der Goethe-Universität, Frankfurt am Main, Germany under the committee’s reference number: 397/11. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).
: Consent for publication was given by selected patient via institutional consent form.
: FL receives support from the Frankfurter Förderung “Nachwuchswissenschaftler” and the EUTOS funding program. FL and OO had advisory roles for Novartis, Ariad, Sanofi Aventis and Bristol-Myers Squibb. F. received funding of Novartis. OO was funded by Novartis, Bristol-Myers Squibb and the Deutsche José Carreras Leukämie Stiftung. All other authors declare no competing interests.